Autoimmune State, SARS-CoV-2 Infection
Conditions
Keywords
SARS-CoV-2, Vaccine
Brief summary
Preliminary data support a possible molecular mimicry between SARS-CoV-2 and autologous components. This suggests the occurrence of autoimmunity during COVID-19. Consistently, autoimmunity may occur after SARS-CoV2 vaccination. The study aims to investigate the production of autoantibodies after vaccination in healtcare workers.
Detailed description
Healtcare workers undergoing SARS-CoV-2 vaccination (with RNA-vaccines) will be included on a voluntary basis. Blood samples will be collected before and after vaccination (1 -3 - 6 - 12 months). All the vaccination side effects will be registered.
Interventions
DIAGNOSTIC_TESTBlood sampling
Detection of ANA, AMA, anti-dsDNA, anti-ENA, anti-MPO, anti-PR3, aPL, RF, ACPA, anti- TPO, anti-TG
Sponsors
Istituto Auxologico Italiano
Study design
Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Healthcare workers undergoing SARS-CoV-2 vaccination
Exclusion criteria
* Pregnancy * Full blown autoimmune diseases * Active vaccinations within 3 months before enrolment (excluding the influenza vaccine) * Previous vaccination severe side effects
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Autoantibody Levels | Before vaccination and 1, 6 and 12 months after vaccination | ANA, AMA, anti-dsDNA, anti-ENA, anti-MPO, anti-PR3, aPL, RF, ACPA, anti-TPO, anti-TG |
Countries
Italy
Outcome results
None listed